Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N1HW
|
|||
| Former ID |
DNC000859
|
|||
| Drug Name |
L-745,870
|
|||
| Synonyms |
158985-00-3; L-745870; UNII-J3OLN3XSX7; J3OLN3XSX7; L-745,870; CHEMBL267014; L 745,870; 3-((4-(4-Chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine; 3-(4-[4-Chlorophenyl]piperazin-1-yl)-methyl-1H-pyrrolo[2,3-b]pyridine trihydrochloride; 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine; 3-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-1H-pyrrolo[2,3-b]pyridine; CPMPP-3; Tocris-1002; Lopac-L-131; Biomol-NT_000049; AC1NSK75; L745870; Lopac0_000791; GTPL3303; BPBio1_001299; SCHEMBL1059886; CHEBI:92099
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H19ClN4
|
|||
| Canonical SMILES |
C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)Cl
|
|||
| InChI |
1S/C18H19ClN4/c19-15-3-5-16(6-4-15)23-10-8-22(9-11-23)13-14-12-21-18-17(14)2-1-7-20-18/h1-7,12H,8-11,13H2,(H,20,21)
|
|||
| InChIKey |
OGJGQVFWEPNYSB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 158985-00-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5007730, 7979687, 11056334, 11111360, 11113847, 14850833, 24263007, 26752020, 39340909, 47365384, 47736667, 47880157, 48110628, 48254023, 50070526, 50071164, 50104687, 50924052, 53787753, 57304374, 57359386, 84970653, 85209133, 85788363, 90340721, 103165750, 103947633, 114155529, 124750001, 124880510, 124880511, 124880512, 128805148, 134341004, 135275785, 135710076, 136351193, 136897518, 137035783, 143160225, 162222310, 164779492, 170485727, 178100340, 179293898, 203086700, 223259268, 227308076, 252432821
|
|||
| ChEBI ID |
CHEBI:92099
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3303). | |||
| REF 2 | Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77. | |||
| REF 3 | Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J Med Chem. 2001 Apr 12;44(8):1151-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.